CHAI is committed to eliminating HCV. We have developed a strategy that aims to cure over 16 million people in 34 countries over the next ten years. Since 2015, CHAI has helped governments in six countries initiate public HCV programs to simplify patient diagnosis and monitoring and lower the costs of medications to save millions of lives. We have helped, through market shaping and price negotiations, lower the cost of treatment by 81 to 97 percent (depending on the country), from an average of US$2,618 to as low as US$60 per cure. Since the program’s inception, over 100,000 patients have been initiated on treatment in the countries where we work. This initial push has demonstrated effective models that can serve as guides to the countries that follow.

To help prevent new HBV infections, we are partnering with Gavi, The Vaccine Alliance, as well as governments, to organize programs to administer the HBV birth dose more effectively. We are leveraging existing relationships with national HIV, HCV and maternal health/antenatal care programs to support the integration of HBV diagnosis and treatment within already established systems.